This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. (Mladen Antonov/AFP/Getty Images/TNS)

This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. (Mladen Antonov/AFP/Getty Images/TNS)

A look at promising and overhyped COVID therapies after a tumultuous year of research

Here’s a look at some of the drugs – deemed effective and not – that made headlines in recent months

Alongside the headline-grabbing race for a COVID-19 vaccine, the hunt for effective treatments has unfolded with its own share of flameouts and triumphs.

Thanks to large randomized trials in the United Kingdom and elsewhere, administering steroids to patients with moderate or severe illness has become part of standard care, but clinicians say few other tools have emerged.

The best known COVID-19 drug is likely dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant effects for hospitalized patients who need help breathing.

But while that drug is credited with helping efforts to bring down hospital mortality rates, credit also goes to discoveries about what does not work against the novel coronavirus – thereby ensuring people get appropriate care.

Here’s a look at some of the drugs – deemed effective and not – that made headlines in recent months for fostering hype and hope:

Health-Canada approved

Remdesivir – Sold under the name Veklury, this Gilead Sciences drug was among various treatments given to former U.S. President Donald Trump when he successfully overcame COVID-19 last year. But its ability to cut deaths has since been largely discounted by a World Health Organization trial. An earlier study by Gilead found the drug helped moderately ill patients recover more quickly if given for five days, but that benefit was less clear if given over 10 days.

Health Canada noted clinical trial data was limited when it approved remdesivir for COVID-19 last July but said “given the high unmet medical need and emergency context of the COVID-19 pandemic, Health Canada considered the balance of benefit and harm for Veklury to be positive.”

Bamlanivimab – The federal government paid US$32.5 million for 26,000 doses of this monoclonal antibody that targets the spike protein of SARS-CoV-2. Eli Lilly says an intravenous infusion can ease and prevent COVID-19 symptoms among mild-to-moderate cases in high-risk groups including seniors.

Nevertheless, it has yet to be embraced by clinicians, with Hamilton infectious disease physician Zain Chagla calling it “a good example of a drug that might work on paper but really isn’t a great drug to invest in.”

The associate professor of medicine at McMaster University points to barriers to implementation, which include the staffing and time required to implement the transfusion.

Alberta Health Services says it’s considering a trial to determine “potential for benefit and feasibility of use” while British Columbia said Monday a clinical trial in Surrey would be funded by AbCellera, the Vancouver company which helped discover bamlanivimab.

Cautions against early hype

Hydroxychloroquine – Commonly used to treat lupus and rheumatoid arthritis, this drug earned infamy when U.S. President Donald Trump touted its efficacy with COVID-19 before the science was in. Since then, multiple rigorous trials have concluded it offers no benefit to preventing or treating illness while underscoring the dangers of mixing politics and science.

Colchicine –Just last week, the Quebec government cautioned clinicians against embracing this anti-inflammatory as a COVID-19 therapy after the Montreal Heart Institute touted the common gout medication as “a major scientific discovery.” Scientists at the National Institute for Excellence in Health and Social Services acknowledged the institute’s study showed positive results, but said the benefit was too small.

Other contenders

Tocilizumab –Dr. Niall Ferguson, head of critical care at the University Health Network and Sinai Health System, sees potential in early data for tocilizumab, approved for use in Canada to treat rheumatoid arthritis. Although evolving data has been mixed and is still emerging, Ferguson notes the monoclonal antibody is already being used off-label for some severe patients.

Heparin – Canadian scientists involved in a global trial for this blood thinner say interim data suggests it can keep some moderately ill COVID-19 patients from deteriorating further. University Health Network scientist Ewan Goligher says the probability of requiring life support dropped by about a third among subjects. He expects the study’s findings to be released soon.

Peginterferon-lambda – Research into this prospective antiviral treatment was recently published in Lancet Respiratory Medicine. Lead researcher Dr. Jordan Feld, a liver specialist at UHN’s Toronto Centre for Liver Disease, says a small Phase 2 trial found it significantly sped recovery for outpatients. Although more research is needed, he suspected it could offer an important way to quickly bring down the virus level in infected patients and reduce their risk of spreading disease to others.

Cassandra Szklarski, The Canadian Press

Like us on Facebook and follow us on Twitter.

Want to support local journalism? Make a donation here.

Coronavirus

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Traffic impacts in the downtown Kitimat area are expected to be finished by 4:30 p.m. (Jacob Lubberts photo)
Traffic impact in the downtown Kitimat area

The impacted intersections are Haisla/Lahakas intersection and Kuldo/Haisla intersection

“Skeena,” by John Hudson and Paul Hanslow is one of five fonts in the running to become the default for Microsoft systems and Office programs. (Black Press Media File Photo)
Font named after Skeena River could become the next Microsoft default

One of the five new fonts will replace Calibri, which has been Microsoft’s default since 2007

Water will be turned off in Service Centre on May 5th, from 9 p.m. to 5 a.m. (Black Press Media files)
Water in Service Centre will be turned off for system repairs

The water will be turned off on, May 5th from 9 p.m. until the following day at 5 a.m.

The Tamitik Status of Women Association has been receiving anti-racism funding since 2018 and has done a multitude of initiatives over the years. Unable to host in-person events, the TSWA plans to host virtual workshops for all who identify as a woman in Kitimat and Kitamaat Village. (Black Press file)
Tamitik Status of Women Association receive $7,500 in anti-racism funding

TSWA plans to hold women’s gathering events and engage with local government about diversity policies

A Rapid Word Collection workshop took place in 2020 where the Haisla community recorded thousands of words to help them reclaim their language. (Haisla Nation video screenshot)
Haisla reclaim their native language through word collection workshops

Over 10,000 words and 5,000 recordings are now available online

Protesters attempt to stop clear-cutting of old-growth trees in Fairy Creek near Port Renfrew. (Will O���Connell photo)
VIDEO: Workers, activists clash at site of Vancouver Island logging operation

Forest license holders asking for independent investigation into incident

Flow Academy is located at 1511 Sutherland Avenue in Kelowna. (Michael Rodriguez/Capital News)
Interior Health locks out Kelowna martial arts gym following COVID violations

Actions were taken after all other steps to gain compliance were exhausted, says health authority

A man who allegedly spat at and yelled racial slurs at an Asian family was arrested for hate-motivated assault Tuesday. (Black Press Media file photo)
Arrest made after man spits, yells anti-Asian racial slurs at Victoria mom and kids

The man was arrested for hate-motivated assault near Quadra Elementary School Tuesday

A lady wears a vaccinated sticker after receiving a COVID-19 vaccine at a vaccination clinic run by Vancouver Coastal Health, in Richmond, B.C., Saturday, April 10, 2021. THE CANADIAN PRESS/Jonathan Hayward
Canada may find it challenging to reach herd immunity from COVID-19, experts say

Level of immunity among the population changes with the variants, especially the more transmissible strains

B.C.’s provincial health officer, Dr. Bonnie Henry. THE CANADIAN PRESS/Jonathan Hayward
Dip in COVID-19 cases with 572 newly announced in B.C.

No new deaths have been reported but hospitalized patients are up to 481, with 161 being treated in intensive care

Solar panels on a parking garage at the University of B.C. will be used to separate water into oxygen and hydrogen, the latter captured to supply a vehicle filling station. (UBC video)
UBC parkade project to use solar energy for hydrogen vehicles

Demonstration project gets $5.6M in low-carbon fuel credits

FILE – A student arrives at school as teachers dressed in red participate in a solidarity march to raise awareness about cases of COVID-19 at Ecole Woodward Hill Elementary School, in Surrey, B.C., on Tuesday, February 23, 2021. THE CANADIAN PRESS/Darryl Dyck
B.C. ‘should be able to’ offer 1st dose of COVID vaccine to kids 12+ by end of June: Henry

Health Canada authorized the vaccine for younger teens this morning

A woman in the Harrison Mills area was attacked by a cougar on Tuesday, May 4. B.C. Conservation Officers killed two male cougars in the area; the attack was determined to be predatory in nature. (File photo)
2 cougars killed following attack on woman in Agassiz area

Attack victim remains in hospital in stable condition

Most Read